Results 1 to 10 of about 52,475 (270)

A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk

Frontiers in Cardiovascular Medicine
ObjectiveRivaroxaban and dabigatran are approved to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF). However, the clinical benefits of rivaroxaban and dabigatran in people with high bleeding risk are unclear.MethodsA ...
Penghui Liu
doaj   +2 more sources

Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation

Frontiers in Pharmacology, 2021
Rivaroxaban is commonly used for the prophylaxis of venous thromboembolism (VTE) for patients undergoing major orthopedic surgery. Rivaroxaban is primarily eliminated by hepatic CYP450 metabolism and renal excretion.
Rui-juan Xu, Rui-juan Xu, Tao Ling, Hong Tang, Wei-hong Ge, Qing Jiang   +5 more
doaj   +1 more source

Evaluating Rivaroxaban for Thromboprophylaxis in Cancer Patients with Long-Term Venous Access Devices: A Retrospective Cohort Study. [PDF]

Vasc Health Risk Manag
Jia B, Lv H, Gong T, Wang X, Ma Q, Ren Y, Zhang L, Zhong D.   +7 more
europepmc   +3 more sources

Rivaroxaban‐calibrated chromogenic anti‐Xa assay in cirrhosis: Use to rule out disseminated intravascular coagulation

Research and Practice in Thrombosis and Haemostasis, 2021
Peritoneovenous shunts (PVSs) are used to relieve ascites in cirrhosis. Disseminated intervascular coagulation (DIC) is a complication of PVSs requiring immediate PVS removal.
Fabienne Lucas, Michael S. Stecker, Olga Pozdnyakova, Jean M. Connors, Elisabeth M. Battinelli   +4 more
doaj   +1 more source

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin

Research and Practice in Thrombosis and Haemostasis, 2021
Background Rivaroxaban may induce heavy menstrual bleeding. It is unknown if this effect is dose related or if rivaroxaban is associated with more menstrual bleeding than aspirin. Objectives To demonstrate and compare menstrual patterns and actions taken
Kochawan Boonyawat, Anthonie W. A. Lensing, Martin H. Prins, Jan Beyer‐Westendorf, Paolo Prandoni, Ida Martinelli, Saskia Middeldorp, Akos F. Pap, Jeffrey I. Weitz, Mark Crowther   +9 more
doaj   +1 more source

Non‐synonymous alterations in AKR7A3 and ABCA6 correlate with bleeding in aged patients treated with rivaroxaban

Clinical and Translational Science, 2022
Rivaroxaban is an oral anticoagulant that inhibits thrombin and blocks coagulation cascade through directly inactivating factors Xa. Despite rivaroxaban is widely used for prevention and treatment of venous thrombosis, and its common adverse reactions ...
Ming Zhao, Qiang Zhang, Xizi Wang, Qianqian Zhang, Conghui Tian, Rongrong Li, Xiaodong Jia, Mingliang Gu, Liping Yang   +8 more
doaj   +1 more source

Evaluation of Herb–Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes

Frontiers in Pharmacology, 2022
The combination of Salvia miltiorrhiza (Danshen) and rivaroxaban is a promising treatment option in clinical practice in China, but the herb–drug interaction between Danshen and rivaroxaban remains unclear.
Xu Wang, Jingjing Fa, Yuanjin Zhang, Shengbo Huang, Jie Liu, Junqing Gao, Lina Xing, Lina Xing, Zongjun Liu, Zongjun Liu, Xin Wang   +10 more
doaj   +1 more source

Anticoagulant effects of rivaroxaban, prednisone, alone and in combination, in healthy dogs

Journal of Veterinary Internal Medicine, 2022
Background The potential effects of glucocorticoid administration on rivaroxaban's anticoagulant bioactivity in dogs, and an appropriate rivaroxaban dosage regimen for dogs receiving glucocorticoid therapy are unknown. Hypothesis/Objectives The objective
Paige M. Hafner, Andrew J. Mackin, Robert W. Wills, Marjory B. Brooks, John M. Thomason   +4 more
doaj   +1 more source

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. [PDF]

, 2020
Background Reducing major bleeding events is a challenge when managing anticoagulation in patients with atrial fibrillation. This study evaluated the impact of modifiable and nonmodifiable bleeding risk factors in patients with atrial fibrillation ...
Amarenco, P, Camm, AJ, Haas, S, Hess, S, Kirchhof, P, Lambelet, M, Turpie, AGG, van Eickels, M, XANTUS Investigators*   +8 more
core   +2 more sources

Real-world experience in managing atrial fibrillation in patients with renal impairment; Rivaroxaban versus warfarin

Heart Views, 2023
Background: The use of rivaroxaban in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) poses the risk of over- or underdosing. We aimed to compare rivaroxaban and warfarin in AF patients with moderate and severe renal impairment ...
Monirah Abdulrahman Albabtain, Zaid Dakheel Alanazi, Nawaf Hamoud Al-Mutairi, Ola Alyafi, Raneem Albanyan, Amr A Arafat   +5 more
doaj   +1 more source